Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GT-02287

Small molecule · developed by Gain Therapeutics

Phase 1 Most advanced trial

GANX Developer

1 Registered trials

What is GT-02287?

GT-02287 is an orally administered powder formulated in sachets of 200 mg for reconstitution with a suspending agent. It is being studied in Parkinson disease, with dosing given as a daily weight-based oral dose over 90 days.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Gain Therapeutics, Inc. (GANX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06732180	Phase 1	Parkinson Disease	Recruiting	GANX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson Disease

Sources

ClinicalTrials.gov NCT06732180

Updated Oct 11, 2026. Something wrong or missing? Report it on the GANX page.

Follow GANX, the company behind GT-02287

See GANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GANX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z